

Press release 2014-08-08

WntR received approval for faster recruitment in Foxy-5 phase 1 study

WntResearch AB today announces that it has received approval from the Danish Health authorities and the Ethic Committee to treat the second and third patient in a dose level simultaneously. Until now all patients have been treated consecutively. This new amendment will improve our recruitment of patients into the study and thereby strengthen our clinical development plans.

CEO Nils Brünner comments:

"We are very happy to be allowed to treat second and third patient simultaneously. This is possible because we have had no toxicity issues with Foxy-5 when administered to the cancer patients."

For further information please contact:

Nils Brünner, CEO
E-mail: nbr@wntresearch.com
Telephone: +45 2614 4708

About Foxy-5

Foxy-5 is an anti-metastatic drug candidate in clinical Phase 1. Foxy-5 represents a new concept (first-in-class) in the treatment of cancer. The drug candidate aims directly at the metastatic process. The spread of the tumor is the most common reason of death for cancer patients. Foxy-5 is one of the first anti-metastatic drug candidates to be investigated in the clinical setting. Foxy-5 offers a potential shift in the anticancer treatment paradigm in the treatment of many large cancer indications including breast-, colon, and prostate cancer.

About WntResearch

WntResearch (WNT.ST) is a public company listed at AktieTorget. WntResearch is developing novel anti-metastatic therapies for the treatment of cancer patients with metastasis. The company's lead product Foxy-5 is in phase 1 and Box-5 is in pre-clinical phase. The company is focusing on Foxy-5.